Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease

This study has been completed.
Sponsor:
Collaborator:
Forest Laboratories
Information provided by (Responsible Party):
Florida Atlantic University
ClinicalTrials.gov Identifier:
NCT00476008
First received: May 17, 2007
Last updated: June 9, 2014
Last verified: June 2014
  Purpose

The purpose of the study is to determine whether memantine delays the progression of driving impairment in patients with mild Alzheimer's Disease (AD).


Condition Intervention Phase
Alzheimer's Disease
Drug: Memantine
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease

Resource links provided by NLM:


Further study details as provided by Florida Atlantic University:

Primary Outcome Measures:
  • The Primary Outcome Measure is the Number of Subjects in Each Group Who Are Able to Pass the DriveABLE On-Road Test at Month 12 (Endpoint). [ Time Frame: Baseline and 12 months ] [ Designated as safety issue: No ]
    The DriveABLE On-Road Test utilizes a standardized road course and standardized scoring procedures designed to identify driving errors indicative of decline in competence scores. This road test takes approximately 30-45 minutes and covers a distance of approximately 9 miles.


Secondary Outcome Measures:
  • Fuld Object Memory Evaluation [ Time Frame: baseline and 12 months ] [ Designated as safety issue: No ]

    Ten common objects in a bag were presented to determine whether the subject could identify objects by touch. The subject was not told that memory of this event would be tested. The subject names each object and then pulls it out of the bag to see if he is correct. After distracting the subject, by asking the patient to say words rapidly from a single category (rapid verbal retrieval), the subject is asked to recall the objects from the bag. The subject was then offered two more chances to learn and recall them (store and retrieve) by reminding the subject of omitted items after each recall, with rapid verbal retrieval preventing rehearsal before each recall opportunity.

    Retrieval scores were summed over the three trials with the range of possible scores being 0-30. Lower scores indicate more severe impairment.


  • Rey Complex Figure Test [ Time Frame: baseline and 12 months ] [ Designated as safety issue: No ]
    This is a measure of visual-spatial and constructional ability as well as higher order cognitive processes including planning, organizing, and problem solving. Subjects are asked to copy a complicated drawing. 18 elements are scored from 0-2 depending on accuracy/distortion and location of the reproduction. The maximum score is 36 points. Lower scores indicate more severe impairment

  • Trail Making Test - Part A [ Time Frame: baseline and 12 months ] [ Designated as safety issue: No ]
    A simple test of visual tracking. The score is the time in seconds required to complete. Higher scores indicate lower functioning.

  • Trail Making Test - Part B [ Time Frame: baseline and 12 months ] [ Designated as safety issue: No ]
    This tests cognitive flexibility and set-shifting. It is considered to be a test of executive functioning and has been shown to correlate with on-road driving ability. The score is the time in seconds required to complete each part. Higher scores indicate decreased functioning.

  • Mini Mental Status Exam [ Time Frame: baseline and 12 months ] [ Designated as safety issue: No ]
    Scores range from 0-30 with lower scores indicating decreased functioning.

  • Useful Field of View [ Time Frame: baseline and 12 months ] [ Designated as safety issue: No ]
    The Useful Field of View is a computer-administered test that measures higher order processing skills such as divided attention and visual processing speed. Scores can be predictive of ability to perform many everyday activities, such as driving a vehicle. Speed of visual processing is measured as the examinee identifies a target, but must also localize a simultaneously presented target displayed in the periphery of the computer monitor. Scores range from 1 to 4 with 1 being no impairment, 2= mild, 3= moderate and 4=serious impairment.

  • Motor Free Visual Perception Test - Visual Closure Subtest [ Time Frame: baseline and 12 months ] [ Designated as safety issue: No ]
    This is an 11 item multiple choice test of visual perception. Scores range from 0-11. This test measures visual perception deficits separate from motor skill abilities. Higher scores indicate more severe impairment.

  • Cognitive Dementia Rating Scale [ Time Frame: baseline and 12 months ] [ Designated as safety issue: No ]
    This scale is used to stage severity of dementia. Scores are on a five-point scale in which 0 indicates no cognitive impairment, .5 = very mild dementia,1 = mild, 2 = moderate and 3= severe.

  • Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) [ Time Frame: baseline and 12 months ] [ Designated as safety issue: No ]
    The ADAS-Cog is a performance based test that measures specific cognitive and behavioral dysfunctions in patients with Alzheimer's disease. The cognitive subscale comprises 11 items which measure word recall (0-10), ability to follow single and multi-step commands (0-5), constructional praxis (0-5), ideational praxis (0-5), naming objects(0-5), word recognition (0-12), orientation (0-8), comprehension of spoken language (0-5), word finding difficulty(0-5) and ability to remember test instructions (0-5). 0 = no impairment with higher scores indicating more severe impairment.


Enrollment: 60
Study Start Date: July 2007
Study Completion Date: October 2012
Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
One tablet placebo morning and evening (BID) for 12 months
Drug: Placebo
One tablet placebo morning and evening (BID) for 12 months
Active Comparator: Memantine
One tablet memantine (Namenda)10mg morning and evening (BID) for 12 months.
Drug: Memantine
One tablet memantine (Namenda)10mg morning and evening (BID) for 12 months
Other Name: Namenda

Detailed Description:

It is well known, and of great concern to both patients and families, that individuals with Alzheimer's disease (AD) eventually become driving impaired. Drivers with dementia are estimated to be 2-8 times more likely to be involved in an automobile crash as unimpaired peers. Approximately half of individuals with mild AD have the skills needed to drive safely. Formal driver evaluation may be necessary to make this distinction. Some reviews in the literature have suggested that individuals identified as high risk, such as those with AD, be advised by their physicians to cease driving altogether. Other studies suggest that these individuals may continue to drive for up to 4 years following diagnosis. Memantine may be effective in delaying the progression of driving impairment in individuals with mild AD. If the investigators can demonstrate a significant delay in the decline in the driving ability, this could extend their driving time and therefore be of immense benefit to patients and their caregivers.

Comparison(s): Subjects treated with memantine over a period of 12 months, compared to subjects on placebo.

  Eligibility

Ages Eligible for Study:   60 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men and women ages 60 years of age and older
  • Subjects must either be previously diagnosed with mild Alzheimer's Disease (AD) by a neurologist, psychiatrist, geriatrician, or be evaluated at a Memory Disorders Center prior to entry into the study
  • Subjects must have a score of ≥ 23 on the Mini-Mental State Examination (MMSE) at the Screening Visit
  • Subjects must receive a passing score on the DriveABLE test
  • Female subjects must be at least 2 years post-menopausal or surgically sterile
  • Written informed consent must be obtained from the subject prior to the initiation of any study specific procedures

Exclusion Criteria:

  • Subjects who have been treated with a depot neuroleptic within six (6) months of the Screening Visit
  • Subjects who fail the OPTEC vision test at the screening visit
  • Subjects who score > 7 on the Hachinski Test at the screening visit
  • Subjects with evidence of clinically significant and active pulmonary, gastrointestinal, renal, hepatic, endocrine or cardiovascular system disease (subjects with controlled hypertension, right bundle branch block [complete or partial] and pacemakers may be included in the study). Subjects with thyroid disease may also be included in the study, provided they are euthyroid on treatment. Subjects with controlled diabetes may also be included
  • Recent (< 2years) B12 or folate deficiency that was considered clinically significant
  • Subjects with evidence of other psychiatric/neurologic disorders including, but not limited to, stroke, Vascular Dementia, Lewy-Body Disease, Parkinson's Disease, seizure disorder, head injury with loss of consciousness within the past 5 years, any psychotic disorder, or bipolar disorder
  • Subjects who are taking, or have taken, amantadine, ketamine, dextromethorphan that cannot be discontinued or switched to an allowable alternative medication prior to the minimum allowable interval before Baseline
  • Subjects who have been in an investigational drug study or who have received treatment with an investigational drug within 30 days (or 5 half-lives, whichever is longer) of the Screening Visit
  • Any condition, which would make the subject, in the opinion of the investigator, unsuitable for the study
  • If subjects are taking Acetylcholinesterase inhibitors (AChEls), they must be on a stable dose for > 3 months prior to baseline. No initiation of AChEls is permitted; discontinuation and dose reduction are permitted
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00476008

Locations
United States, Florida
Charles E. Schmidt College of Medicine, Florida Atlantic University
Boca Raton, Florida, United States, 33431
Sponsors and Collaborators
Florida Atlantic University
Forest Laboratories
Investigators
Principal Investigator: Peter J Holland, MD Charles E, Schmidt College of Medicine at Florida Atlantic University
  More Information

No publications provided

Responsible Party: Florida Atlantic University
ClinicalTrials.gov Identifier: NCT00476008     History of Changes
Other Study ID Numbers: NAM-MD-49
Study First Received: May 17, 2007
Results First Received: September 20, 2013
Last Updated: June 9, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Florida Atlantic University:
Alzheimer's Disease
Mild Alzheimer's Disease
Driving
Driving Impairment

Additional relevant MeSH terms:
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Memantine
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Antiparkinson Agents
Anti-Dyskinesia Agents
Central Nervous System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on July 20, 2014